Growth Differentiation Factor-15 and Syndecan-1 Are Potential Biomarkers of Cardiac and Renal Involvement in Classical Fabry Disease under Enzyme Replacement Therapy
Background and Aims: Inflammation and endothelial damage play a pivotal role in Fabry disease (FD) manifestations. In daily clinical practice, FD is mainly monitored by traditional biomarkers of target organ injury, such as serum creatinine and proteinuria, which provide no information about inflamm...
Saved in:
Main Authors: | Paulo C. Gregório (Author), Gilson Biagini (Author), Regiane S. da Cunha (Author), Júlia Budag (Author), Ana Maria Martins (Author), Lara Valiño Rivas (Author), Elberth M. Schiefer (Author), Maria Dolores Sánchez-Niño (Author), Alberto Ortiz (Author), Andréa E. M. Stinghen (Author), Fellype C. Barreto (Author) |
---|---|
Format: | Book |
Published: |
Karger Publishers,
2022-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disease Progression Modeling to Evaluate the Effects of Enzyme Replacement Therapy on Kidney Function in Adult Patients with the Classic Phenotype of Fabry Disease
by: Albina Nowak, et al.
Published: (2017) -
Enzyme replacement therapy for Fabry disease: some answers but more questions
by: Majid Alfadhel, et al.
Published: (2011) -
Clinical features and enzyme replacement therapy in 10 children with Fabry disease
by: Qian Li, et al.
Published: (2023) -
Fabry nephropathy before and after enzyme replacement therapy: important role of renal biopsy in patients with Fabry disease
by: Il Young Kim, et al.
Published: (2021) -
Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease
by: V. I. Ignatyeva, et al.
Published: (2019)